Overview

Clinical Endpoint Study of Ivermectin 0.5% Lotion

Status:
Completed

Trial end date:
2018-03-12

Target enrollment:

Participant gender:

Summary

This clinical study is designed to evaluate the clinical (therapeutic) effect of a generic ivermectin lotion 0.5% (Actavis Laboratories UT, Inc.) relative to that of the Food and Drug Administration (FDA) Reference Listed Drug (RLD) SKLICE® (ivermectin) lotion, 0.5% (Arbor Pharmaceuticals, LLC) in participants with active head lice infestation. Additionally, both the test and reference (that is; the RLD) treatments were tested for superiority to a placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Actavis Inc.

Collaborator:

Teva Pharmaceuticals USA

Treatments:

Ivermectin